Quantcast

Better Coronavirus Stock: Novavax (NVAX) or Vaxart (VXRT)?

Novavax (NASDAQ:NVAX) and Vaxart (NASDAQ:VXRT) have practically become household names in 2020, largely thanks to their efforts to develop vaccines for COVID-19. Both of these companies have also performed exceptionally well on the stock market of late. Year to date, shares of Novavax are up by 4,210%, while Vaxart’s stock is up by 2,660% over the same period. It may […]

Continue Reading ...
  • The 4 BEST-PERFORMING Mega Cap Technology Stocks YTD

    While the pandemic caused immense losses for many businesses, certain stocks continued to soar. These businesses were able to capitalize on changes in the economy. Mega-cap technology stocks were the biggest beneficiary as their operations and products were unaffected by social distancing or shutdowns. Additionally, interest rates plunged following the crash and Fed’s actions which […]

    Continue Reading ...
  • 3 Recently DOWNGRADED Tech Stocks to Avoid

    Technology is attractive to investors, because there is potential for fast growth and big margins.  And as a sector, technology it’s one of the strongest areas of the market, as the Nasdaq is 6% above its pre-coronavirus highs and 57% above its March lows. Yet, even though the bull market in technology is creating a […]

    Continue Reading ...
  • 4 Stocks That Can Hit a $1 Trillion Valuation Next

    For most companies, the coronavirus disease 2019 (COVID-19) pandemic represents one of the most disruptive events they’re ever navigated through. But for the market’s largest companies, it’s represented an opportunity to get even bigger. Despite historic stock market volatility, the tech-heavy Nasdaq Composite has hit more than two dozen all-time highs in 2020, with Apple, Microsoft, Amazon, and Alphabet, the parent […]

    Continue Reading ...
  • 3 Growth Stocks I’d Buy Right Now

    The future is even more unclean than normal for investors these days. Stocks have been roaring since late March, but it’s difficult to deny the coronavirus contagion has proven problematic for the economy. And all indications are that the upcoming earnings season will be rife with ugly results. Nevertheless, there are some growth names too […]

    Continue Reading ...